NKTX - Nkarta: NK Cell Therapy Advancement On Two Fronts

2024-03-25 16:03:27 ET

Summary

• Release of results from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory NHL, expected mid-2024; this is using a compressed dosing schedule.
• The global non-Hodgkin's Lymphoma market is expected to reach $20 billion by the end of 2036.
• NKX019 is also being used to target patients with autoimmune disorders like Lupus Nephritis; the first patient in the phase 1 study is to be dosed in 1st half of 2024.
• Nkarta had $250.9 million in cash as of December 31, 2023, to fund its operations into 2026. Despite this cash runway, a public offering of $240 million was expected to close in March 2024.

Nkarta, Inc. ( NKTX ) is gearing up to report results from its phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory non-Hodgkin's lymphoma [NHL]. Such data is going to be released by mid-2024 and will determine if this biotech is going to continue to advance the use of this particular natural killer [NK] cell therapy to target this r/r patient population. This is crucial because the company went away from original dosing and transitioned to compressed dosing of these patients. It was stated that continued advancement of NKX019 for this r/r NHL patient population will only be moved forward with positive data. Hopefully, the data will turn out to be good and this program can move forward....

For further details see: